FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572547868> ?p ?o ?g. }

• W2572547868 abstract "Abstract Multiple myeloma (MM)-associated bone disease is caused by upregulation of osteoclast (OCL) activity and constitutive inhibition of osteoblast function. The extracellular signal-regulated kinase 1/2 (ERK1/2) MAP kinase pathway contributes to cytokine-induced OCL differentiation and maturation. We hypothesized that inhibition of ERK1/2 could prevent OCL differentiation and downregulate OCL function. Here we investigate the effects of AZD6244, which blocks the ERK1/2 MAPK pathway via direct inhibition of MEK1/2, on OCL in MM. Peripheral blood mononuclear cells (PBMC) from healthy donors (n=3) and MM patients (n=11) were harvested and stimulated with RANKL (50ng/ml) and M-CSF (25ng/ml) for 2 weeks to induce OCL formation, in the presence or absence of AZD6244. OCL characteristics were measured by flow cytometric analysis of anti-alphaVbeta3 integrin expression. AZD6244 inhibited OCL differentiation in a dose-dependent manner (n=11, median control: 77.4% at 0 uM; 77% at 0.02 uM; 54% at 0.2 uM; 53% at 2 uM; 38% at 5 uM; 29% at 10 uM). TRAP staining (tartrate-resistant acid phosphatase) was performed to identify OCL and to confirm activity. Importantly, AZD6244 inhibited OCL in a dose-dependent manner, as evidenced by a marked loss of TRAP+ cells. To assess bone resorption activity, OCL were cultured with dentine discs in the presence or absence of AZD6244, followed by the measurement of soluble collagen I fragments in the supernatant. AZD6244 inhibited bone resorption in a dose-dependent manner. We next asked whether AZD6244 affects mature OCL. Mature OCL were induced by cytokine stimulation for 2 weeks and then AZD6244 was added for 3 days, followed by flow cytometric analysis. AZD6244 had no effect on total number of alphaVbeta3 integrin-expressing mature OCL (n=6). Two major myeloma growth and survival factors produced by OCL, B-cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL), were measured in OCL culture supernatants by ELISA. AZD6244 significantly inhibited secretion of BAFF and APRIL. In addition, macrophage inflammatory protein (MIP-1alpha), an important OCL differentiation factor and MM survival factor, was inhibited. These results indicate that AZD6244 inhibits OCL differentiation induced by M-CSF and RANKL, leading to reduced bone resorption activity. Moreover, AZD6244 downregulates MIP-1alpha and BAFF, APRIL secretion by OCL, which could inhibit MM cell survival in the bone marrow microenvironment. We have also demonstrated that AZD6244 inhibits proliferation and survival of human MM cell lines, either sensitive or resistant to conventional chemotherapy, as well as freshly isolated patient MM cells (Abstract #553572 and #553605, ASH 2006). In conclusion, the present study provides a preclinical rationale for the evaluation of AZD6244 (ARRY-142886) as a potential new therapy for patients with MM." @default.
• W2572547868 created "2017-01-26" @default.
• W2572547868 creator A5000190395 @default.
• W2572547868 creator A5006765393 @default.
• W2572547868 creator A5019802024 @default.
• W2572547868 creator A5032464400 @default.
• W2572547868 creator A5035612207 @default.
• W2572547868 creator A5045740077 @default.
• W2572547868 creator A5052048627 @default.
• W2572547868 creator A5070221339 @default.
• W2572547868 creator A5090686439 @default.
• W2572547868 creator A5091207345 @default.
• W2572547868 date "2006-11-16" @default.
• W2572547868 modified "2023-09-30" @default.
• W2572547868 title "AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications." @default.
• W2572547868 doi "https://doi.org/10.1182/blood.v108.11.3467.3467" @default.
• W2572547868 hasPublicationYear "2006" @default.
• W2572547868 type Work @default.
• W2572547868 sameAs 2572547868 @default.
• W2572547868 citedByCount "2" @default.
• W2572547868 crossrefType "journal-article" @default.
• W2572547868 hasAuthorship W2572547868A5000190395 @default.
• W2572547868 hasAuthorship W2572547868A5006765393 @default.
• W2572547868 hasAuthorship W2572547868A5019802024 @default.
• W2572547868 hasAuthorship W2572547868A5032464400 @default.
• W2572547868 hasAuthorship W2572547868A5035612207 @default.
• W2572547868 hasAuthorship W2572547868A5045740077 @default.
• W2572547868 hasAuthorship W2572547868A5052048627 @default.
• W2572547868 hasAuthorship W2572547868A5070221339 @default.
• W2572547868 hasAuthorship W2572547868A5090686439 @default.
• W2572547868 hasAuthorship W2572547868A5091207345 @default.
• W2572547868 hasConcept C134018914 @default.
• W2572547868 hasConcept C137061746 @default.
• W2572547868 hasConcept C153911025 @default.
• W2572547868 hasConcept C170493617 @default.
• W2572547868 hasConcept C180675623 @default.
• W2572547868 hasConcept C184235292 @default.
• W2572547868 hasConcept C185592680 @default.
• W2572547868 hasConcept C202751555 @default.
• W2572547868 hasConcept C2776033226 @default.
• W2572547868 hasConcept C2779428903 @default.
• W2572547868 hasConcept C502942594 @default.
• W2572547868 hasConcept C55493867 @default.
• W2572547868 hasConcept C57074206 @default.
• W2572547868 hasConcept C673006 @default.
• W2572547868 hasConcept C86803240 @default.
• W2572547868 hasConcept C88045685 @default.
• W2572547868 hasConcept C95444343 @default.
• W2572547868 hasConceptScore W2572547868C134018914 @default.
• W2572547868 hasConceptScore W2572547868C137061746 @default.
• W2572547868 hasConceptScore W2572547868C153911025 @default.
• W2572547868 hasConceptScore W2572547868C170493617 @default.
• W2572547868 hasConceptScore W2572547868C180675623 @default.
• W2572547868 hasConceptScore W2572547868C184235292 @default.
• W2572547868 hasConceptScore W2572547868C185592680 @default.
• W2572547868 hasConceptScore W2572547868C202751555 @default.
• W2572547868 hasConceptScore W2572547868C2776033226 @default.
• W2572547868 hasConceptScore W2572547868C2779428903 @default.
• W2572547868 hasConceptScore W2572547868C502942594 @default.
• W2572547868 hasConceptScore W2572547868C55493867 @default.
• W2572547868 hasConceptScore W2572547868C57074206 @default.
• W2572547868 hasConceptScore W2572547868C673006 @default.
• W2572547868 hasConceptScore W2572547868C86803240 @default.
• W2572547868 hasConceptScore W2572547868C88045685 @default.
• W2572547868 hasConceptScore W2572547868C95444343 @default.
• W2572547868 hasLocation W25725478681 @default.
• W2572547868 hasOpenAccess W2572547868 @default.
• W2572547868 hasPrimaryLocation W25725478681 @default.
• W2572547868 hasRelatedWork W1985834045 @default.
• W2572547868 hasRelatedWork W2040181826 @default.
• W2572547868 hasRelatedWork W2325615145 @default.
• W2572547868 hasRelatedWork W2383493120 @default.
• W2572547868 hasRelatedWork W2537357476 @default.
• W2572547868 hasRelatedWork W2802240459 @default.
• W2572547868 hasRelatedWork W2808736031 @default.
• W2572547868 hasRelatedWork W2950808982 @default.
• W2572547868 hasRelatedWork W3125269118 @default.
• W2572547868 hasRelatedWork W4200503771 @default.
• W2572547868 isParatext "false" @default.
• W2572547868 isRetracted "false" @default.
• W2572547868 magId "2572547868" @default.
• W2572547868 workType "article" @default.